Affinity Biosciences Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Affinity Biosciences's estimated annual revenue is currently $1.4M per year.(i)
  • Affinity Biosciences's estimated revenue per employee is $155,000

Employee Data

  • Affinity Biosciences has 9 Employees.(i)
  • Affinity Biosciences grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.8M50%N/AN/A
#2
$1.7M110%N/AN/A
#3
$0.8M50%N/AN/A
#4
$5.1M3314%N/AN/A
#5
$64.6M4172%N/AN/A
#6
$1.7M11-8%N/AN/A
#7
$0.8M50%N/AN/A
#8
$7.4M48-41%N/AN/A
#9
$0.6M40%N/AN/A
#10
$0.9M1220%N/AN/A
Add Company

What Is Affinity Biosciences?

Founded in 2006, Affinity Biosciences is a pioneering Life Science and High-Tech company whose biochemical products and services are mainly applied in biotechnology, medical research and pharmaceutical development. Dedicating to advancing customer success through innovation, Affinity Biosciences has established R&D affiliates in the United Kingdom and United States with the aim of providing outstanding service around the globe.Our customers include scientists and technologists in life science companies, university and government institutions, hospitals and industry. To underline our commitment to our customers and enhance our standards of service, we have opened packaging and quality control facilities in the People’s Republic of China. Our goal is to develop high-quality antibody that focuses on Cell Signaling Transduction research, including Akt,AMPK,NF-KappaB,TGF-beta,etc,as well as inhibitors and related reagents.

keywords:N/A

N/A

Total Funding

9

Number of Employees

$1.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Affinity Biosciences News

2022-04-17 - Movers & Shakers, April 15: Spruce, Nautilus, Alto, Ikena ...

Spruce Biosciences: Libbie Mansell was named chief regulatory and quality ... of affinity reagent development at Seattle-based Nautilus.

2022-04-17 - BridGene Biosciences Announces Acceptance of Two Abstracts for Poster Presentations at Cambridge Health Institute's Inaugural Drug Discovery Chemistry Conference

The posters highlight the use of the Company's proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) platform in small...

2022-04-06 - Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors

TAB009/JS009 binds specifically to CD112R with high affinity and effectively blocks the interaction between CD112R and its ligand CD112, thereby...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M9N/AN/A
#2
$1.2M913%N/A
#3
$0.7M90%N/A
#4
$0.7M90%N/A
#5
$0.7M90%N/A